Natick, United States
Avenge Bio, established in 2019, is an innovative player in the Biotechnology and Health Care sectors, headquartered in the United States. The company is committed to advancing cancer treatment through its cutting-edge LOCOcyteTM platform, aimed at overcoming the challenges associated with treating solid tumors.
Avenge Bio's novel platform facilitates the precise delivery of cytokines and other potent immunomodulatory molecules, which promises robust anti-tumor responses while minimizing typical immunotherapy-associated toxicities. This approach stems from the extensive research of Dr. Omid Veiseh at Rice University.
Supported by notable investors, such as Longitude Capital, Pappas Capital, CAM Capital, Perceptive Advisors, and Rock Springs Capital, Avenge Bio raised a significant $45.00M in a Series A round on January 5, 2022. This financial backing underlines confidence in Avenge Bio's potential to revolutionize cancer treatment through their promising therapeutic pipeline.
